Total n = 17 (%) |
Adjuvant Group n = 5 (%) |
Palliative Group n = 6 (%) |
Control Group n = 6 (%) | P value | ||
---|---|---|---|---|---|---|
Age (Mean ± SD) | 55.6 ± 8.6 | 53.4 ± 4.7 | 60.0 ± 12.5 | 53.2 ± 5.1 | 0.324 | |
Sex | 0.133 | |||||
F | 4 (23.5) | 0 (0) | 1 (16.7) | 3 (50.0) | ||
M | 13 (76.5) | 5 (100.0) | 5 (83.3) | 3 (50.0) | ||
Viral Hepatitis | 0.135 | |||||
HBV | 11 (64.7) | 4 (80.0) | 5 (83.3) | 2 (33.3) | ||
HCV | 6 (35.3) | 1 (20.0) | 1 (16.7) | 4 (66.7) | ||
C-P Classification | 0.522 | |||||
A | 10 (58.8) | 4 (80.0) | 2 (33.3) | 4 (66.7) | ||
B | 4 (23.5) | 1 (20.0) | 2 (33.3) | 1 (16.7) | ||
C | 3 (17.6) | 0 (0) | 2 (33.3) | 1 (16.7) | ||
Pre-OLT BCLC Staging | 0.011 | |||||
A | 1 (5.9) | 1 (20.0) | 0 (0) | 0 (0) | ||
B | 6 (35.3) | 4 (80.0) | 1 (16.7) | 1 (16.7) | ||
C | 7 (41.2) | 0 (0) | 2 (33.3) | 5 (83.3) | ||
D | 3 (17.6) | 0 (0) | 3 (50.0) | 0 (0.0) | ||
Donor Type | 0.624 | |||||
CD | 15 (88.2) | 5 (100) | 5 (83.3) | 5 (83.3) | ||
LD | 2 (11.8) | 0 (0) | 1 (16.7) | 1 (16.7) | ||
1 st Relapse Site | 0.052 | |||||
Liver | 6 (35.3) | 1 (20.0) | 2 (33.3) | 3 (50.0) | ||
Lung | 4 (23.5) | 0 (0) | 2 (33.3) | 2 (33.3) | ||
Portal vein | 2 (11.8) | 0 (0) | 2 (33.3) | 0 (0.0) | ||
No relapse | 5 (29.4) | 4 (80.0) | 0 (0) | 1 (16.7) |